Fig. 1 · Structure

Documents & Downloads

Capecitabine

Cat. No. A10177 CAS 154361-50-9

Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR), to form 5-fluorouracil.

In Stock

Publications for Capecitabine

4 publications citing this product

  1. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  2. Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489
  3. Azuma T, .et al. , Environ Sci Pollut Res Int, 2017, Aug;24(23):19021-19030 PMID: 28660504
  4. Azuma T, .et al. , Sci Total Environ, 2016, Apr 1;548-549:189-197 PMID: 26802347

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Thymidine phosphorylase

Cellular Effect

Cell Line Activity Value Description Reference
HCT-116 IC50 34.2 μM Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 35300092]
HeLa IC50 0.05 mg/mL Cytotoxicity against human HeLa cells after 3 days MTT assay [PMID: 22796042]
KG-1 IC50 8.9 μM Antiproliferative activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 35300092]
MCF7 IC50 0.71 mg/mL Cytotoxicity against human MCF7 cells after 3 days MTT assay [PMID: 22796042]
NCI-H69 IC50 0.3 mg/mL Cytotoxicity against human NCI-H69 cells after 3 days MTT assay [PMID: 22796042]

In Vitro Studies

In MDA-MB-453 breast cancer cells, DUSP6 depletion increased sensitivity to capecitabine plus neratinib in a 48 h WST-1 assay. This combination experiment does not establish capecitabine-alone potency or activation in these cells. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

DUSP6 depletion and a capecitabine–neratinib combination

Cell-based study · HER2+ MDA-MB-453 breast cancer cells; scrambled siRNA control and DUSP6 knockdown, with or without the drug combination. [1]

DUSP6 depletion increased sensitivity to the capecitabine–neratinib combination after 48 h. The experiment evaluates a combination and genetic perturbation; it does not isolate capecitabine monotherapy activity or establish its metabolic activation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability after 48 hWST-1 relative viability DUSP6 knockdown plus capecitabine/neratinib reduced viability relative to the drug combination or knockdown alone (****p<0.0001).[1]

Literature-Reported Treatment Conditions

Exposure duration
48 h drug treatment
Method
WST-1 assay; DUSP6 siRNA perturbation compared with scrambled control.
Vehicle
DMSO; final concentration did not exceed 0.1% [v/v] in treatments.
Co-treatment
Capecitabine plus neratinib, with or without DUSP6 knockdown.
Reported limits
Drug doses are not specified in Figure 4E/caption or the retrieved relevant methods. Linked Figure 4 source data returned HTML, not a usable ZIP. Exact siRNA identity in Table EV1 was not retrieved; no sequence-specific mechanism claim is adopted.
Methods and source locations

Compound reported in the paper: Capecitabine; Compound label in the paper: Capecitabine with neratinib

Qualitative response to the named drug combination under DUSP6 depletion; no capecitabine-only potency, lot equivalence or clinical efficacy claim.

Reagents; Cell Culture and Transfections; Cell growth assays; Results paragraph on DUSP6 depletion and capecitabine; Figure 4E and caption

Cell viability after 48 h: Three independent experiments, each in triplicate; one-way ANOVA followed by Tukey multiple comparisons (Figure 4E caption). — Reagents; Cell Culture and Transfections; Cell growth assays; Results paragraph on DUSP6 depletion and capecitabine; Figure 4E and caption

In Vivo Studies

In SW620 colorectal xenografts, oral capecitabine plus vorinostat inhibited tumor growth more than either agent alone. At the tested doses, single agents had no significant effect on tumor-growth delay. The reported survival endpoint was time to a tumor-size euthanasia threshold. [2]

Capecitabine and vorinostat in SW620 xenografts

Animal study · SW620 human colorectal cancer xenografts in female BALB/c athymic nude mice; four randomized groups, n=9 per group. [2]

The combination inhibited tumor growth more than the individual treatments. Capecitabine alone at the tested dose produced only slight growth inhibition and no significant tumor-growth-delay effect. Survival was defined by reaching a tumor-size euthanasia threshold, rather than spontaneous mortality.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volume and tumor growth delayQualitative comparison Combination greater than single-agent treatments; single agents showed no significant TGD effect.[2]
Time to tumor-size euthanasia endpointKaplan–Meier comparison P=0.03, combination vs control[2]

Conditions shared by the study groups

Frequency
5 days/week
Treatment course
Two weeks
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlBoth drug vehiclesComparator for tumor growth and survival.[2]
Capecitabine alone
359 mg kg−1
Both drug vehiclesSlight growth inhibition; no significant TGD effect.[2]
Vorinostat alone
100 mg kg−1
Both drug vehiclesSlight growth inhibition; no significant TGD effect.[2]
Capecitabine plus vorinostat
Capecitabine 359 mg kg−1; vorinostat 100 mg kg−1
Both drug vehiclesGreater tumor-growth inhibition than single agents; survival comparison vs control P=0.03.[2]
Vehicle control
Model: SW620 xenograft; n=9 mice per group
Vehicle: Capecitabine: 40 mM citrate buffer (pH 6) containing 5% gum arabic. Vorinostat: DMSO diluted in PEG.
Capecitabine alone
Model: SW620 xenograft; n=9 mice per group
Route: p.o.
Vehicle: 40 mM citrate buffer (pH 6), 5% gum arabic
Vorinostat alone
Model: SW620 xenograft; n=9 mice per group
Route: p.o.
Vehicle: DMSO diluted in PEG
Capecitabine plus vorinostat
Model: SW620 xenograft; n=9 mice per group
Route: p.o.
Vehicle: Capecitabine: 40 mM citrate buffer (pH 6) containing 5% gum arabic. Vorinostat: DMSO diluted in PEG.
Methods and source locations

Compound reported in the paper: Capecitabine; Compound label in the paper: Capecitabine (Xeloda)

Applies to capecitabine as named, not validation of the Adooq lot or a clinical dosing recommendation.

Materials and Methods: Materials, In vivo xenograft assay, Statistics; Results: In vivo synergistic antitumour effect; Figure 5A–D and caption

Tumor volume and tumor growth delay: Caliper tumor-volume measurements; TGD from time to a fixed tumor volume. — Materials and Methods: Materials, In vivo xenograft assay, Statistics; Results: In vivo synergistic antitumour effect; Figure 5A–D and caption

Time to tumor-size euthanasia endpoint: Figure 5D caption; killing at approximately 2000 mm³ counted as death. — Figure 5D and caption; In vivo xenograft assay

Vehicle control · Materials and Methods: Materials, In vivo xenograft assay, Statistics; Results: In vivo synergistic antitumour effect; Figure 5A–D and caption

Capecitabine alone · Materials and Methods: Materials, In vivo xenograft assay, Statistics; Results: In vivo synergistic antitumour effect; Figure 5A–D and caption

Vorinostat alone · Materials and Methods: Materials, In vivo xenograft assay, Statistics; Results: In vivo synergistic antitumour effect; Figure 5A–D and caption

Capecitabine plus vorinostat · Materials and Methods: Materials, In vivo xenograft assay, Statistics; Results: In vivo synergistic antitumour effect; Figure 5A–D and caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 154361-50-9
Formula C15H22FN3O6
Molecular Weight 359.4
Synonyms Captabin; Xeloda
SMILES
CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 62 mg/mL (172.53 mM)
Water 5 mg/mL (13.91 mM)
Ethanol 62 mg/mL (172.53 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Momeny M, Tienhaara M, Sharma M, et al. DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. EMBO molecular medicine (2024). PMID: 38886591 DOI: 10.1038/s44321-024-00088-0 Source material
  2. [2] Di Gennaro E, Piro G, Chianese MI, et al. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. British journal of cancer (2010). PMID: 21045833 DOI: 10.1038/sj.bjc.6605969 Source material

Publications

4 publications citing this product

  1. Majid Momeny, .et al. , EMBO Mol Med, 2024, Jun 17 PMID: 38886591
  2. Takashi Azuma, .et al. , SEP PURIF TECHNOL, 2019, Apr; 212: 483-489
  3. Azuma T, .et al. , Environ Sci Pollut Res Int, 2017, Aug;24(23):19021-19030 PMID: 28660504
  4. Azuma T, .et al. , Sci Total Environ, 2016, Apr 1;548-549:189-197 PMID: 26802347

Added to your cart

View Cart Checkout
Loading...